600
Participants
Start Date
July 18, 2023
Primary Completion Date
November 28, 2025
Study Completion Date
November 28, 2025
Active case detection using molecular testing (ACDm)
In the ACDm arm, children will receive ACD using RDT and qPCR 3x yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. With fevers, participants will receive standard PCD using RDT.
Passive case detection using molecular testing (PCDm)
With fevers, participants will receive PCDm, in which qPCR will be done in RDT negatives with treatment using AL if positive.
Control (standard of care)
With fevers, participants will receive standard PCD using RDT with treatment using AL if positive.
Kiwangwa and Fukayosi clinics, Bagamoyo
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Ifakara Health Institute
OTHER
Swiss Tropical & Public Health Institute
OTHER
Stanford University
OTHER
Chan Zuckerberg Biohub
OTHER
University of California, San Francisco
OTHER